@article{ref1,
title="Management site and level of health care for cannabis- and synthetic cannabinoid-related poison control center cases involving older adults, 2016-2019",
journal="Drug and chemical toxicology",
year="2021",
author="Baker, S. David and Marti, C. Nathan and Dinitto, Diana M. and Choi, Namkee G.",
volume="ePub",
number="ePub",
pages="ePub-ePub",
abstract="Increasing numbers of older adults use cannabis and cannabis-derived products that can have adverse effects. This study examined management site and level of  healthcare services for older adult poison control center cases involving cannabis  products. Using the American Association of Poison Control Centers' (PCC) National  Poison Data System, 2016-2019, we extracted the 3109 cases aged 50+ for which  cannabis was the only or primary substance. Multinomial logistic regression models  were fit to examine associations between specific cannabis forms and management/care  site (on site [mostly at home], at a healthcare facility [HCF], or no follow-up due  to referral refusal or leaving against medical advice) and level of healthcare  services for cases managed at a HCF. The results show that between 2016 and 2019,  PCC cannabis cases involving older adults increased twofold, largely due to cases of  cannabidiol, edibles, and concentrated extracts. Plant form and synthetic  cannabinoid cases declined substantially. Compared to plant forms, synthetic  cannabinoid cases had 4.22 (95% CI = 2.59-6.89) greater odds of being managed at,  rather than outside, a HCF and 2.17 (1.42-3.31) greater odds of critical care unit  admission. Although e-cigarette cases, compared to plant form cases, had lower odds  of being managed at a HCF, HCF-managed e-cigarette cases had 3.43 greater odds (95%  CI = 1.08-10.88) of critical care unit admission. Synthetic cannabinoid cases also  had 1.86 (95% CI = 1.03-3.35) greater odds of no follow-up, and the presence of a  secondary substance was also a significant factor. Stricter regulations for listing  chemical ingredients and providing safety guidelines are needed for cannabis-derived  products.<p /> <p>Language: en</p>",
language="en",
issn="0148-0545",
doi="10.1080/01480545.2020.1868494",
url="http://dx.doi.org/10.1080/01480545.2020.1868494"
}